跳转至内容
Merck
  • Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study.

Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study.

Journal of breath research (2015-01-06)
Wojciech Filipiak, Ronny Beer, Andreas Sponring, Anna Filipiak, Clemens Ager, Alois Schiefecker, Simon Lanthaler, Raimund Helbok, Markus Nagl, Jakob Troppmair, Anton Amann
摘要

Existing methods for the early detection of infections in mechanically ventilated (MV) patients at intensive care units (ICUs) are unsatisfactory. Here we present an exploratory study assessing the feasibility of breath VOC analyses for the non-invasive detection of pathogens in the lower respiratory tract of ventilated patients. An open uncontrolled clinical pilot study was performed by enrolling 28 mechanically ventilated (MV) patients with severe intracranial disease, being at risk for the development of or already with confirmed ventilation-associated pneumonia (VAP). The recently developed sampling technique enabled the collection of breath gas with a maximized contribution of alveolar air directly from the respiratory circuit under continuous capnography control, adsorptive preconcentration and final analysis by means of gas chromatography-mass spectrometry (GC-MS).VAP was confirmed in 22/28 preselected patients (78%). The most common microorganisms were Staphylococcus aureus (5/22 VAP patients), Escherichia coli (5/22 VAP patients) and Candida spp. (5/22 VAP patients). 12/32 metabolites released by S. aureus in our previous in vitro studies were also detected in the end-tidal air of VAP patients infected with this pathogen. A similar overlap was seen in Candida albicans infections (8/29 VOCs). Moreover, the concentration profile of selected compounds correlated with the course of the infection.This prospective pilot study provides proof of the concept that the appearance and the concentration profile of pathogen-derived metabolites (elucidated from in vitro experiments) in the breath of ventilated patients during clinically confirmed VAP correlates with the presence of a particular pathogen.

材料
货号
品牌
产品描述

Sigma-Aldrich
活性炭 Norit®, Norit® PK 1-3, from peat, steam activated, granular
Sigma-Aldrich
活性炭 Norit®, Norit® GAC 1240W, from coal, for potable water processing, steam activated, granular
Sigma-Aldrich
活性炭 Norit®, Norit® SX ultra, from peat, corresponds U.S. Food chemicals codex (3rd Ed.), steam activated and acid washed, highly purified, powder
Sigma-Aldrich
碳,介孔, nanopowder, less than 500 ppm Al, Ti, Fe, Ni, Cu, and Zn combined
Sigma-Aldrich
活性炭 Norit®, Norit® RB3, for gas purification, steam activated, rod
Sigma-Aldrich
活性炭 Norit®, Norit® SX2, powder, from peat, multi-purpose activated charcoal, steam activated and acid washed
Sigma-Aldrich
碳,介孔, less than 100 ppm Al, Ti, Fe, Ni, Cu, and Zn combined
Sigma-Aldrich
碳,介孔
Sigma-Aldrich
碳,介孔, hydrophilic pore surface
Supelco
活性炭 Norit®, Norit® RBAA-3, rod
Sigma-Aldrich
甲烷, ≥99.0%
Carbon - Vitreous, rod, 100mm, diameter 5.0mm, glassy carbon
Carbon - Vitreous, foam, 150x150mm, thickness 2.5mm, bulk density 0.05g/cm3, porosity 96.5%
Carbon - Vitreous, foil, 25x25mm, thickness 0.5mm, glassy carbon
Sigma-Aldrich
甲烷-12C, 13C-去除, 99.9 atom % 12C
Carbon - Vitreous, rod, 5mm, diameter 3.0mm, glassy carbon
Carbon - Vitreous, rod, 100mm, diameter 3.0mm, glassy carbon
Carbon - Vitreous, foam, 150x150mm, 0.05g.cmué, porosity 96.5%, 24 pores/cm
Carbon - Vitreous, foil, 50x50mm, thickness 1.0mm, glassy carbon
Carbon - Vitreous, tube, 100mm, outside diameter 10mm, inside diameter 3mm, wall thickness 3.5mm, glassy carbon
Carbon - Vitreous, tube, 50mm, outside diameter 10mm, inside diameter 3mm, wall thickness 3.5mm, glassy carbon